Share-Based Compensation (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs |
Equity awards compensation expense recorded in the consolidated statements of operations was as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | General and Administrative | | | | | | Total equity awards compensation expense (1) | | | | | | Tax benefit from equity awards compensation expense | | | | | | Total equity awards compensation expense, net of tax effect | | | | | |
(1) The periods ended December 31, 2025 and 2024, are presented net of $5.8 million and $4.0 million, respectively, capitalized stock-based compensation relating to internally developed software. The breakdown of the equity award compensation expense by instrument type was as follows: | | | | | | | | | | | | | | | | Restricted stock units and Performance stock units | | | | | | | | | | | | | | | | | | | | | | | | Total equity awards compensation expense (1) | | | | | | Tax benefit from equity awards compensation expense | | | | | | Total equity awards compensation expense, net of tax effect | | | | | |
(1) The periods ended December 31, 2025 and 2024, are presented net of $5.8 million and $4.0 million, respectively, capitalized stock-based compensation relating to internally developed software.
|
| Schedule of Nonvested Restricted Stock Units Activity |
| | | | | | | Weighted- Average Grant Date Fair Value Per Share | | | Outstanding as of December 31, 2024 | | | | | | | | | | | | | | | | Outstanding as of December 31, 2025 | | | |
|
| Share-Based Payment Arrangement, Performance Shares, Activity |
The number of shares granted, vesting and outstanding subject to performance conditions is as follows: | | | | | | | Weighted- Average Grant Date Fair Value Per Share | | | Outstanding as of December 31, 2024 | | | | | | | | Performance share adjustment | | | | | | | | | | | | Outstanding as of December 31, 2025 | | | |
|
| Schedule of Share Based Compensation Performance Shares Award Total Shareholder Return Unvested Activity |
The grant-date fair value was determined based on a Monte-Carlo valuation model using the following key assumptions: | | Expected volatility of the Company | | Expected volatility of the benchmark | | | | | |
The number of shares granted, vested and outstanding subject to market conditions is as follows: | | | | | | | Weighted- Average Grant Date Fair Value Per Share | | | Outstanding as of December 31, 2024 | | | | | | | | | | | | | | | | Outstanding as of December 31, 2025 | | | |
|
| Schedule of Stockholders' Equity Note, Warrants or Rights |
| | | | | | | | | | | Weighted- Average Grant Date Fair Value Per Share | | Weighted- Average Remaining Contractual Term (Years) | | Aggregate Intrinsic Value (in thousands) | | | | | | | Outstanding - December 31, 2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Outstanding - December 31, 2025 | | | | | | | | | | | | | | | | Vested and exercisable - December 31, 2025 | | | | | | | |
|
| Schedule of Stock Options Roll Forward |
| | | | | | | | | | Number of Shares Underlying Outstanding Options | | Weighted- Average Exercise Price | | Weighted- Average Remaining Contractual Term (Years) | | Aggregate Intrinsic Value (in thousands) | | | | Outstanding - December 31, 2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Outstanding - December 31, 2025 | | | | | | | | | | | | | | | | Vested and exercisable - December 31, 2025 | | | | | | | |
|